GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
GSK continued a run of several consecutive quarters of solid growth in the fourth quarter of 2022, helped by shingles vaccine Shingrix, but it needs to build up its pipeli
Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds.
This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosc
The FDA has started its review of Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, fast-tracking the biologics license application (BLA) with a decision due in May 2023.